179 related articles for article (PubMed ID: 37962868)
1. Rapid Access to Potent Bispecific T Cell Engagers Using Biogenic Tyrosine Click Chemistry.
Shajan I; Rochet LNC; Tracey SR; Jackowska B; Benazza R; Hernandez-Alba O; Cianférani S; Scott CJ; van Delft FL; Chudasama V; Albada B
Bioconjug Chem; 2023 Dec; 34(12):2215-2220. PubMed ID: 37962868
[TBL] [Abstract][Full Text] [Related]
2. Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer.
Szijj PA; Gray MA; Ribi MK; Bahou C; Nogueira JCF; Bertozzi CR; Chudasama V
Nat Chem; 2023 Nov; 15(11):1636-1647. PubMed ID: 37488375
[TBL] [Abstract][Full Text] [Related]
3. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
4. Geometric Antibody Engineering Reveals the Spatial Factor on the Efficacy of Bispecific T Cell Engagers.
Zhang Y; Yang Z; Saimi D; Shen X; Ye J; Yu B; Pefaur N; Scheer JM; Nixon AE; Chen Z
ACS Chem Biol; 2024 Apr; 19(4):916-925. PubMed ID: 38491942
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia.
Caracciolo D; Riillo C; Ballerini A; Gaipa G; Lhermitte L; Rossi M; Botta C; Duroyon E; Grillone K; Gallo Cantafio ME; Buracchi C; Alampi G; Gulino A; Belmonte B; Conforti F; Golino G; Juli G; Altomare E; Polerà N; Scionti F; Arbitrio M; Iannone M; Martino M; Correale P; Talarico G; Ghelli Luserna di Rorà A; Ferrari A; Concolino D; Sestito S; Pensabene L; Giordano A; Hildinger M; Di Martino MT; Martinelli G; Tripodo C; Asnafi V; Biondi A; Tagliaferri P; Tassone P
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33597219
[TBL] [Abstract][Full Text] [Related]
6. Preparation of bispecific antibody-protein adducts by site-specific chemo-enzymatic conjugation.
Bartels L; Ploegh HL; Spits H; Wagner K
Methods; 2019 Feb; 154():93-101. PubMed ID: 30081077
[TBL] [Abstract][Full Text] [Related]
7. Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies.
Hays P
Cancer Treat Res; 2022; 183():287-315. PubMed ID: 35551665
[TBL] [Abstract][Full Text] [Related]
8. [Bispecific antibodies: An old story with a bright future… with CAR-T cells!].
Riffard C; Teillaud JL
Bull Cancer; 2021 Oct; 108(10S):S168-S180. PubMed ID: 34920800
[TBL] [Abstract][Full Text] [Related]
9. Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity.
Wagner K; Kwakkenbos MJ; Claassen YB; Maijoor K; Böhne M; van der Sluijs KF; Witte MD; van Zoelen DJ; Cornelissen LA; Beaumont T; Bakker AQ; Ploegh HL; Spits H
Proc Natl Acad Sci U S A; 2014 Nov; 111(47):16820-5. PubMed ID: 25385586
[TBL] [Abstract][Full Text] [Related]
10. Construction of a novel TROP2/CD3 bispecific antibody with potent antitumor activity and reduced induction of Th1 cytokines.
Wang D; Zhang L; Wang B; Zhao L; Deng L; Xu W; Huang H
Protein Expr Purif; 2023 May; 205():106242. PubMed ID: 36746324
[TBL] [Abstract][Full Text] [Related]
11. PSMA-targeted bispecific Fab conjugates that engage T cells.
Patterson JT; Isaacson J; Kerwin L; Atassi G; Duggal R; Bresson D; Zhu T; Zhou H; Fu Y; Kaufmann GF
Bioorg Med Chem Lett; 2017 Dec; 27(24):5490-5495. PubMed ID: 29126850
[TBL] [Abstract][Full Text] [Related]
12. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
[TBL] [Abstract][Full Text] [Related]
13. Chemically generated IgG2 bispecific antibodies through disulfide bridging.
Patterson JT; Gros E; Zhou H; Atassi G; Kerwin L; Carmody L; Zhu T; Jones B; Fu Y; Kaufmann GF
Bioorg Med Chem Lett; 2017 Aug; 27(16):3647-3652. PubMed ID: 28720505
[TBL] [Abstract][Full Text] [Related]
14. Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety.
Ellerman D
Methods; 2019 Feb; 154():102-117. PubMed ID: 30395966
[TBL] [Abstract][Full Text] [Related]
15. Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.
Rozan C; Cornillon A; Pétiard C; Chartier M; Behar G; Boix C; Kerfelec B; Robert B; Pèlegrin A; Chames P; Teillaud JL; Baty D
Mol Cancer Ther; 2013 Aug; 12(8):1481-91. PubMed ID: 23757164
[TBL] [Abstract][Full Text] [Related]
16. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
[TBL] [Abstract][Full Text] [Related]
17. Computational simulations of bispecific T cell engagers by a multiscale model.
Su Z; Almo SC; Wu Y
Biophys J; 2024 Jan; 123(2):235-247. PubMed ID: 38102828
[TBL] [Abstract][Full Text] [Related]
18. Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.
Aschmoneit N; Kühl L; Seifert O; Kontermann RE
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782429
[TBL] [Abstract][Full Text] [Related]
19. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
[TBL] [Abstract][Full Text] [Related]
20. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
Leclercq G; Haegel H; Schneider A; Giusti AM; Marrer-Berger E; Boetsch C; Walz AC; Pulko V; Sam J; Challier J; Ferlini C; Odermatt A; Umaña P; Bacac M; Klein C
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
